Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion

NCT07492680 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07492680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Recruiting
Start date
July 27, 2026
Completion date
May 20, 2032
Enrollment
260 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors